Literature DB >> 3157447

Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody.

P H Hand, A Thor, J Schlom, C N Rao, L Liotta.   

Abstract

It has been hypothesized that epithelial and endothelial cells interact with the laminin component of basement membranes via a cell surface laminin receptor molecule. It has also been proposed that the expression of this molecule may be involved in the invasion of carcinoma cells from their tissue of origin and their subsequent penetration through blood vessel basement membranes. We report here the use of a monoclonal antibody, LR-3, to define the expression of laminin receptor in normal, dysplastic, and carcinomatous human tissues. Monoclonal antibody LR-3 is shown by immunoblotting to recognize the Mr 67,000 laminin receptor protein, to bind to the carcinoma cells, and to constitute approximately 0.1% of total cellular protein. Numerous normal human epithelial and endothelial cell types, as well as pulmonary macrophages, are shown to express laminin receptor to varying degrees. Selected human mammary carcinomas and colon carcinomas are shown to bind more monoclonal antibody LR-3 than normal or dysplastic counterparts. A monoclonal antibody to laminin receptor now makes possible the study of the role of laminin receptor in tumor cell metastases and in the differentiation and function of various normal human epithelial and endothelial cell types.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157447

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression.

Authors:  S Martignone; R Pellegrini; E Villa; N N Tandon; A Mastroianni; E Tagliabue; S Ménard; M I Colnaghi
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

Review 2.  Use of basement membrane markers in tumour diagnosis.

Authors:  A J d'Ardenne
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

3.  Laminin receptors on SCLC cells.

Authors:  E Tagliabue; S Martignone; A Mastroianni; S Ménard; R Pellegrini; M I Colnaghi
Journal:  Br J Cancer Suppl       Date:  1991-06

4.  Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin.

Authors:  U M Wewer; L A Liotta; M Jaye; G A Ricca; W N Drohan; A P Claysmith; C N Rao; P Wirth; J E Coligan; R Albrechtsen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

5.  Expression of a specific protein in spontaneously metastatic fibrosarcoma cell lines and its enhanced synthesis by growth on laminin or fibronectin.

Authors:  J H Youngblom; N Wang; J B McCarthy; M Janatipour; T Wang; J R Sheppard; S S Panter
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

6.  The relationship between 67KD laminin receptor expression and metastasis of hepatocellular carcinoma.

Authors:  S Zheng; Y Ruan; Z Wu; J Tang
Journal:  J Tongji Med Univ       Date:  1997

Review 7.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Control pathways of the 67 kDa laminin binding protein: surface expression and activity of a new ligand binding domain.

Authors:  T H Landowski; S Uthayakumar; J R Starkey
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

9.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

10.  Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency.

Authors:  Maria Fiorentino; Liezhen Fu; Yun-Bo Shi
Journal:  Int J Mol Med       Date:  2009-03       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.